Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs.
Shotaro KojimaTaro IwamotoYoshihisa KobayashiManami KatoFumiyoshi TakizawaTomoaki IdaJunya SuzukiYosuke TodaKazusa MiyachiArifumi IwataShunsuke FurutaKei IkedaHiroshi NakajimaPublished in: RMD open (2024)
RZV is robustly immunogenic and has a clinically acceptable safety profile in elderly patients with RA receiving DMARDs.